Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression [8]

AIDS

Volumn 21, Issue 7, 2007, Pages 889-891

  Streeck, Hendrik ^a,b   Schweighardt, Becky ^c   Jessen, Heiko ^d   Allgaier, Rachel L ^a,b   Wrin, Terri ^c   Stawiski, Eric W ^c   Jessen, Arne B ^d   Allen, Todd M ^a,b   Walker, Bruce D ^a,b   Altfeld, Marcus ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LOPINAVIR; NEUTRALIZING ANTIBODY; RITONAVIR; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE AMPLIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LETTER; MALE; PRIORITY JOURNAL; SUPERINFECTION; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AMINO ACID SEQUENCE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 34147153414     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280f77439     Document Type: Letter

References (11)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
2. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35- Cw*04 disadvantage [see Comments]. Science 1999; 283:1748-1752.
3. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-880.
4. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031- 1038.
5. Machado DM, Delwart EL, Diaz RS, de Oliveira CF, Alves K, Rawal BD, et al. Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS 2002; 16:113-119.
6. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48.
7. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420:434-439.
8. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363:619-622.
9. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
10. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
11. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201-208.